Back to All NewsJulian Rees presents HOPO-101 at Second Annual Research Conference on Global Lead Exposure

Julian Rees presents HOPO-101 at Second Annual Research Conference on Global Lead Exposure

Julian Rees, PhD, Co-Founder and CEO of HOPO Therapeutics, presented "HOPO-101 as a novel treatment for lead poisoning" at the Second Annual Research Conference on Global Lead Exposure, hosted by the Center for Global Development (CGD) and the Partnership for a Lead-Free Future in London on June 3–4, 2026. The conference convened researchers, policymakers, and implementers from around the world working to end lead poisoning, which affects over 800 million children, most in low- and middle-income communities. Julian's talk shared HOPO's work developing the investigational drug HOPO-101 as a potential oral treatment for lead poisoning in adults and children.Watch a recording of the talk